Sanofi's Beyfortus shows hospitalization benefit across two RSV seasons
Source: SeekingAlpha
2026-02-17 04:07:05 ET
More on Sanofi
- Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
- Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
- Sanofi 2025 Q4 - Results - Earnings Call Presentation
- Sanofi replaces CEO Paul Hudson, names Belén Garijo as successor
- Sanofi anticipates profitable growth to continue over at least five years
Read the full article on Seeking Alpha
For further details see:
Sanofi’s Beyfortus shows hospitalization benefit across two RSV seasons
Sanofi
NASDAQ: SNY
SNY Trading
-0.56% G/L:
$44.155 Last:
1,077,036 Volume:
$44.07 Open:
SNY Latest News
February 23, 2026 01:42:29 pm
Kraig Biocraft Laboratories Featured on the Cover of National Geographic
February 18, 2026 08:45:56 am
It's Not Synthetic, It's Real. Kraig Labs Nears Spider Silk Breakthrough
SNY Stock Data
$119,804,457,217
2,430,957,423
N/A
389
N/A
Pharmaceuticals
Healthcare
FR
Paris
